πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11020686

Methods for quantitating individual antibodies from a mixture

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11020495

Humanized low affinity FCΞ³R mouse cells

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11019810

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11013220

Humanized dipeptidyl-peptidase IV (DPP4) animals

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10995150

Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10995146

Methods of treating severe insulin resistance by interfering with glucagon receptor signal

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10988537

Antibodies comprising chimeric constant domains

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975139

Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10973879

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10968278

Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954289

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10947312

Human antibodies to GFRΞ±3 and methods of making thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10947310

Fusion protein comprising apelin and an anti-APLNR antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941210

Anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941208

Anti-MUC16 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941213

Anti-TMPRSS2 antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10940211

Human antibodies to S. aureus hemolysin A toxin

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10939673

Method of using mouse having a humanized cluster of differentiation 47 gene

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10935554

Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specifi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934349

Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that i

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10927435

Compositions for the treatment of rheumatoid arthritis and methods of using same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10925971

Methods of treating PRLR positive breast cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10905784

Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10888601

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted